Natera CEO Steven Chapman sells $12.96m in stock

Published 23/01/2025, 01:48 pm
NTRA
-

The filing also indicates that Chapman acquired shares through the exercise of restricted stock units (RSUs) on January 20 and January 21, 2025, totaling 5,161 shares. These transactions were recorded at a price of $0 per share as part of his compensation package. Following these transactions, Chapman holds 267,629 shares of Natera common stock directly.The sales were reportedly made to cover tax obligations related to the vesting of RSUs, as outlined in written instructions intended to comply with Rule 10b5-1(c) under the Exchange Act. Natera, now valued at $22.7 billion, has demonstrated strong momentum with a 61% price increase over the past six months. Get deeper insights into Natera's valuation and growth prospects with a comprehensive Pro Research Report, available exclusively on InvestingPro. Natera, now valued at $22.7 billion, has demonstrated strong momentum with a 61% price increase over the past six months. Get deeper insights into Natera's valuation and growth prospects with a comprehensive Pro Research Report, available exclusively on InvestingPro.

The filing also indicates that Chapman acquired shares through the exercise of restricted stock units (RSUs) on January 20 and January 21, 2025, totaling 5,161 shares. These transactions were recorded at a price of $0 per share as part of his compensation package. Following these transactions, Chapman holds 267,629 shares of Natera common stock directly.

The sales were reportedly made to cover tax obligations related to the vesting of RSUs, as outlined in written instructions intended to comply with Rule 10b5-1(c) under the Exchange Act.

In other recent news, Natera Inc (NASDAQ:NTRA). has expanded its patent infringement lawsuit against NeoGenomics (NASDAQ:NEO), Inc. The broadened litigation now includes an additional patent, U.S. Patent No. 11,319,596, concerning the RaDaR assay, a test for molecular residual disease. This development follows a series of court decisions, including injunctions against NeoGenomics' earlier versions of the RaDaR test.

In financial news, Natera reported a 64% year-over-year increase in Q3 revenue, reaching a record $439.8 million. The company also conducted 137,000 oncology tests, marking a 54% increase from the previous year. Based on these strong financial results, Natera revised its full-year revenue guidance to between $1.61 billion and $1.64 billion.

Analysts have responded favorably to these recent developments. TD Cowen, Baird, and Jefferies have all maintained positive ratings on Natera's stock, with TD Cowen raising its price target from $175 to $195. These firms expressed confidence in Natera's operational success and future growth.

In other company news, the agreement with Dr. Rabinowitz, the Executive Chairman, has been amended to continue his role under specific conditions outlined in the agreement. Also, Natera faced a setback in a false advertising lawsuit against Guardant Health (NASDAQ:GH), but plans to request the court to overturn the ruling. Despite this, the company remains firm in its disagreement with the decision.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.